Evidence map›Paper›PMID 40347416›Full record

ReviewDiscover oncology2025

Exploring the cancerous nexus: the pivotal and diverse roles of USP39 in cancer development.

Yujing Chen, Jingyi Zhang, Jinfeng Yang, Jiawei Zhao, Xiaotong Guo, Juzheng Zhang, Jinfeng Gan, Weijia Zhao, Siqi Chen, Xinwen Zhang and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yujing Chen *School of Pharmacy, Guilin Medical University, Guangxi, 541199, Guilin, People's Republic of China.
Jingyi Zhang *Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, Guangxi, China.
Jinfeng Yang *Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, Guangxi, China.
Jiawei ZhaoKey Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, Guangxi, China.
Xiaotong GuoKey Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, Guangxi, China.
Juzheng ZhangKey Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, Guangxi, China.
Jinfeng GanKey Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, Guangxi, China.
Weijia ZhaoKey Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, Guangxi, China.
Siqi ChenKey Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, Guangxi, China.
Xinwen ZhangKey Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, Guangxi, China.
Yi LinKey Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, Guangxi, China. 36577544@qq.com.
Jiamin JinSchool of Pharmacy, Guilin Medical University, Guangxi, 541199, Guilin, People's Republic of China. jinjiamin@glmc.edu.cn.

Funding

Guangxi Natural Science Foundation Project 2023GXNSFAA026061Guangxi Natural Science Foundation Project 2023GXNSFBA026313Guangxi Natural Science Foundation Project 2024GXNSFAA010335Guangxi Natural Science Foundation Project 2025GXNSFAA069989Independent project of Guangxi Key Laboratory of Tumor Immunity and Microenvironment Regulation 203030302415National Natural Science Foundation of China 32360170National Natural Science Foundation of China 81802884National Natural Science Foundation of China 82100234National Natural Science Foundation of China 82260602National Natural Science Foundation of China 82460677The open funds of the Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation 2022KF001
6 · The paper itself

Abstract

The ubiquitin-proteasome system enables post-transcriptional protein modification and is a major pathway for the degradation of most of them in eukaryotic cells. Among these, the ubiquitin-specific protease (USP) family is the most extensively studied. As an important member of the USP family, ubiquitin-specific protease 39 (USP39) plays an essential role in RNA splicing and protein regulation. This review comprehensively summarizes the structural characteristics and molecular functions of USP39, emphasizing its pivotal role in the regulation of cellular processes. Dysregulation of USP39 is closely associated with the progression of various cancers through mechanisms such as immune evasion, modulation of oncogenic signaling pathways, and altered RNA splicing. These processes impact key aspects of cancer biology, including proliferation, metastasis, and therapy resistance, underscoring the broad implications of USP39 in tumor progression. Recent studies position USP39 as a promising target for cancer treatment. Future research should explore its upstream regulatory networks, develop small-molecule inhibitors, and evaluate its potential for precision oncology. This review integrates the latest insight into USP39, providing a foundation for its clinical application in cancer therapy.

Indexed as

CancerDeubiquitinationRNA splicingUbiquitin–proteasome system inhibitorsUbiquitin-specific protease 39 (USP39)

Identifiers

PMID40347416
PMCPMC12065690

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.